{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:23:22Z","timestamp":1790619802889,"version":"4.1.0"},"reference-count":157,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>Despite advances over the past decade, malignant melanoma remains associated with poor survival outcomes and an increasing incidence, particularly in older populations. Traditional radio- and chemotherapeutic approaches have shown limited efficacy, whereas immunotherapy has emerged as a promising treatment option owing to the immunogenic nature of most melanoma subtypes. This review aims to explore the biological rationale for immune checkpoint inhibition in melanoma and its therapeutic implications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>Advances in understanding physiologic immune checkpoint regulation through co-stimulatory and co-inhibitory pathways have led to the development of effective immune checkpoint inhibitors (ICIs), particularly those targeting PD-1 and CTLA-4. These agents have significantly improved overall survival in melanoma; however, a substantial proportion of patients either fail to respond or eventually develop resistance. Ongoing clinical studies are elucidating mechanisms of immune evasion, refining response prediction biomarkers, and exploring combination strategies to overcome resistance and enhance durable remission.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Immune checkpoint inhibition represents a major therapeutic milestone in malignant melanoma, transforming outcomes for many patients. Nevertheless, resistance and non-responsiveness remain key clinical challenges. Continued investigation into tumor\u2013immune system interactions and rational combination approaches will be critical for optimizing the efficacy and durability of ICIs in melanoma treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11912-026-01750-1","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T06:21:56Z","timestamp":1772778116000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Immune Checkpoint Inhibitors in Malignant Melanoma: Anti-PD-1, Anti-CTLA-4 and Anti-LAG-3 Therapies"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6522-5620","authenticated-orcid":false,"given":"Andrea M.","family":"Allen-Tejerina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1518-9788","authenticated-orcid":false,"given":"Periklis","family":"Giannakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5510-6214","authenticated-orcid":false,"given":"Thomas","family":"Ho Lai Yau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1011-3220","authenticated-orcid":false,"given":"Christopher R. T.","family":"Hillyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrine S.","family":"Rallis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,6]]},"reference":[{"issue":"2","key":"1750_CR1","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ejcsup.2013.07.012","volume":"11","author":"Z Ali","year":"2013","unstructured":"Ali Z, Yousaf N, Larkin J. Melanoma epidemiology, biology and prognosis. EJC Suppl. 2013;11(2):81\u201391.","journal-title":"EJC Suppl"},{"issue":"3","key":"1750_CR2","first-page":"228","volume":"6","author":"Y Liu","year":"2014","unstructured":"Liu Y, Sheikh MS. Melanoma: molecular pathogenesis and therapeutic management. Mol Cell Pharmacol. 2014;6(3):228.","journal-title":"Mol Cell Pharmacol"},{"issue":"1","key":"1750_CR3","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1056\/NEJMra052166","volume":"355","author":"AJ Miller","year":"2006","unstructured":"Miller AJ, Mihm MC, Melanoma. N Engl J Med. 2006;355(1):51\u201365.","journal-title":"N Engl J Med"},{"key":"1750_CR4","unstructured":"SEER*Explorer: An interactive website for SEER cancer statistics [Internet]. Surveillance Research Program, National Cancer Institute. 2024 Apr 17. [cited 2024 May 10]. Available from: https:\/\/seer.cancer.gov\/statistics-network\/explorer\/. Data source(s): SEER Incidence Data, November 2023 Submission (1975\u20132021), SEER 22 registries (excluding Illinois and Massachusetts). Expected Survival Life Tables by Socio-Economic Standards."},{"issue":"Suppl 23","key":"1750_CR5","doi-asserted-by":"publisher","first-page":"3807","DOI":"10.1002\/cncr.29050","volume":"120","author":"CL Kosary","year":"2014","unstructured":"Kosary CL, Altekruse SF, Ruhl J, Lee R, Dickie L. Clinical and prognostic factors for melanoma of the skin using SEER registries: collaborative stage data collection system, version 1 and version 2. Cancer. 2014;120(Suppl 23):3807\u201314.","journal-title":"Cancer"},{"issue":"6","key":"1750_CR6","doi-asserted-by":"publisher","first-page":"259","DOI":"10.2310\/7750.2006.00066","volume":"10","author":"J Geller","year":"2006","unstructured":"Geller J, Swetter SM, Leyson J, Miller DR, Brooks K, Geller AC. Crafting a melanoma educational campaign to reach Middle-Aged and older men. J Cutan Med Surg. 2006;10(6):259\u201368.","journal-title":"J Cutan Med Surg"},{"issue":"5","key":"1750_CR7","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1634\/theoncologist.8-5-459","volume":"8","author":"FC Beddingfield","year":"2003","unstructured":"Beddingfield FC. The melanoma epidemic: Res Ipsa loquitur. Oncologist. 2003;8(5):459\u201365.","journal-title":"Oncologist"},{"issue":"Suppl 1","key":"1750_CR8","doi-asserted-by":"publisher","first-page":"e2021161S","DOI":"10.5826\/dpc.11S1a161S","volume":"11","author":"C Conforti","year":"2021","unstructured":"Conforti C, Zalaudek I. Epidemiology and risk factors of melanoma: A review. Dermatol Pract Concept. 2021;11(Suppl 1):e2021161S.","journal-title":"Dermatol Pract Concept"},{"issue":"11","key":"1750_CR9","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1586\/era.10.170","volume":"10","author":"E Erdei","year":"2010","unstructured":"Erdei E, Torres SM. A new Understanding in the epidemiology of melanoma. Expert Rev Anticancer Ther. 2010;10(11):1811.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"3","key":"1750_CR10","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.fsc.2009.05.002","volume":"17","author":"J Califano","year":"2009","unstructured":"Califano J, Nance M. Malignant melanoma. Facial Plast Surg Clin N Am. 2009;17(3):337\u201348.","journal-title":"Facial Plast Surg Clin N Am"},{"issue":"1","key":"1750_CR11","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","volume":"9","author":"ZR Chalmers","year":"2017","unstructured":"Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9(1):34.","journal-title":"Genome Med"},{"key":"1750_CR12","unstructured":"Transcriptional downregulation of. MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition | Nature Communications [Internet]. [cited 2021 May 16]. Available from: https:\/\/www.nature.com\/articles\/s41467-020-15726-7"},{"issue":"7","key":"1750_CR13","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.3390\/ijms21072367","volume":"21","author":"V Petrova","year":"2020","unstructured":"Petrova V, Arkhypov I, Weber R, Groth C, Altevogt P, Utikal J, et al. Modern aspects of immunotherapy with checkpoint inhibitors in melanoma. Int J Mol Sci. 2020;21(7):2367.","journal-title":"Int J Mol Sci"},{"key":"1750_CR14","doi-asserted-by":"crossref","unstructured":"Seidel JA, Otsuka A, Kabashima K. Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations. Front Oncol [Internet]. 2018 Mar 28 [cited 2019 Oct 14];8. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5883082\/","DOI":"10.3389\/fonc.2018.00086"},{"issue":"3","key":"1750_CR15","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1042\/EBC20160017","volume":"60","author":"LB Nicholson","year":"2016","unstructured":"Nicholson LB. The immune system. Essays Biochem. 2016;60(3):275\u2013301.","journal-title":"Essays Biochem"},{"issue":"2 Suppl 2","key":"1750_CR16","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.jaci.2009.12.980","volume":"125","author":"DD Chaplin","year":"2010","unstructured":"Chaplin DD. Overview of the immune response. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S3\u201323.","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"1750_CR17","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1016\/j.cell.2024.03.037","volume":"187","author":"H Chi","year":"2024","unstructured":"Chi H, Pepper M, Thomas PG. Principles and therapeutic applications of adaptive immunity. Cell. 2024;187(9):2052\u201378.","journal-title":"Cell"},{"key":"1750_CR18","doi-asserted-by":"crossref","unstructured":"Xing Y, Hogquist KA. T-Cell Tolerance: Central and Peripheral. Cold Spring Harb Perspect Biol [Internet]. 2012 Jun [cited 2019 Dec 9];4(6). Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3367546\/","DOI":"10.1101\/cshperspect.a006957"},{"key":"1750_CR19","unstructured":"Frontiers. | Twenty Years of AIRE | Immunology [Internet]. [cited 2021 May 16]. Available from: https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2018.00098\/full."},{"key":"1750_CR20","doi-asserted-by":"crossref","unstructured":"Regulation of T cell. expansion by antigen presentation dynamics | PNAS [Internet]. [cited 2021 May 16]. Available from: https:\/\/www.pnas.org\/content\/116\/13\/5914","DOI":"10.1073\/pnas.1812800116"},{"issue":"4","key":"1750_CR21","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41577-020-00454-2","volume":"21","author":"MA ElTanbouly","year":"2021","unstructured":"ElTanbouly MA, Noelle RJ. Rethinking peripheral T cell tolerance: checkpoints across a T cell\u2019s journey. Nat Rev Immunol. 2021;21(4):257\u201367.","journal-title":"Nat Rev Immunol"},{"key":"1750_CR22","doi-asserted-by":"crossref","unstructured":"Yun TJ, Clark EA, Cooperation. Mechanisms of Cellular. In: Delves PJ, editor. Encyclopedia of Immunology (Second Edition) [Internet]. Oxford: Elsevier; 1998 [cited 2019 Dec 9]. pp. 651\u20136. Available from: http:\/\/www.sciencedirect.com\/science\/article\/pii\/B0122267656001791","DOI":"10.1006\/rwei.1999.0171"},{"issue":"1","key":"1750_CR23","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/nrneph.2013.183","volume":"10","author":"ML Ford","year":"2014","unstructured":"Ford ML, Adams AB, Pearson TC. Targeting co-stimulatory pathways: transplantation and autoimmunity. Nat Rev Nephrol. 2014;10(1):14\u201324.","journal-title":"Nat Rev Nephrol"},{"issue":"3","key":"1750_CR24","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.21873\/anticanres.14870","volume":"41","author":"KS Rallis","year":"2021","unstructured":"Rallis KS, Hillyar CRT, Sideris M, Davies JK. T-cell-based immunotherapies for haematological Cancers, part A: A SWOT analysis of immune checkpoint inhibitors (ICIs) and bispecific T-Cell engagers (BiTEs). Anticancer Res. 2021;41(3):1123\u201341.","journal-title":"Anticancer Res"},{"issue":"5","key":"1750_CR25","doi-asserted-by":"publisher","first-page":"107241","DOI":"10.1016\/j.jbc.2024.107241","volume":"300","author":"RA Mariuzza","year":"2024","unstructured":"Mariuzza RA, Shahid S, Karade SS. The immune checkpoint receptor LAG3: Structure, function, and target for cancer immunotherapy. J Biol Chem. 2024;300(5):107241.","journal-title":"J Biol Chem"},{"key":"1750_CR26","doi-asserted-by":"crossref","unstructured":"Ledbetter JA, Linsley PS. CD28. In: Delves PJ, editor. Encyclopedia of Immunology (Second Edition) [Internet]. Oxford: Elsevier; 1998 [cited 2019 Dec 9]. pp. 482\u20133. Available from: http:\/\/www.sciencedirect.com\/science\/article\/pii\/B0122267656001316","DOI":"10.1006\/rwei.1999.0126"},{"key":"1750_CR27","doi-asserted-by":"crossref","unstructured":"Mir MA. Chapter 1 - Introduction to Costimulation and Costimulatory Molecules. In: Mir MA, editor. Developing Costimulatory Molecules for Immunotherapy of Diseases [Internet]. Academic Press; 2015 [cited 2019 Dec 9]. pp. 1\u201343. Available from: http:\/\/www.sciencedirect.com\/science\/article\/pii\/B9780128025857000017","DOI":"10.1016\/B978-0-12-802585-7.00001-7"},{"key":"1750_CR28","doi-asserted-by":"crossref","unstructured":"van Nieuwenhuijze A, Liston A. Chapter Four - The Molecular Control of Regulatory T Cell Induction. In: Liston A, editor. Progress in Molecular Biology and Translational Science [Internet]. Academic Press; 2015 [cited 2019 Dec 9]. pp. 69\u201397. (Regulatory T Cells in Health and Disease; vol. 136). Available from: http:\/\/www.sciencedirect.com\/science\/article\/pii\/S1877117315001908","DOI":"10.1016\/bs.pmbts.2015.09.001"},{"key":"1750_CR29","doi-asserted-by":"crossref","unstructured":"Singh SS, Jois SD. Chapter One - Homo- and Heterodimerization of Proteins in Cell Signaling: Inhibition and Drug Design. In: Donev R, editor. Advances in Protein Chemistry and Structural Biology [Internet]. Academic Press; 2018 [cited 2019 Dec 9]. pp. 1\u201359. (Protein-Protein Interactions in Human Disease, Part B; vol. 111). Available from: http:\/\/www.sciencedirect.com\/science\/article\/pii\/S1876162317300640","DOI":"10.1016\/bs.apcsb.2017.08.003"},{"issue":"2","key":"1750_CR30","doi-asserted-by":"publisher","first-page":"e89263","DOI":"10.1371\/journal.pone.0089263","volume":"9","author":"M Sanchez-Lockhart","year":"2014","unstructured":"Sanchez-Lockhart M, Rojas AV, Fettis MM, Bauserman R, Higa TR, Miao H, et al. T cell receptor signaling can directly enhance the avidity of CD28 ligand binding. PLoS ONE. 2014;9(2):e89263.","journal-title":"PLoS ONE"},{"key":"1750_CR31","doi-asserted-by":"crossref","unstructured":"Granier C, Guillebon ED, Blanc C, Roussel H, Badoual C, Colin E et al. Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer. ESMO Open [Internet]. 2017 Jul 1 [cited 2019 Dec 9];2(2). Available from: https:\/\/esmoopen.bmj.com\/content\/2\/2\/e000213","DOI":"10.1136\/esmoopen-2017-000213"},{"key":"1750_CR32","doi-asserted-by":"crossref","unstructured":"Bell RB, Feng Z, Bifulco CB, Leidner R, Weinberg A, Fox BA. 15 - Immunotherapy. In: Bell RB, Fernandes RP, Andersen PE, editors. Oral, Head and Neck Oncology and Reconstructive Surgery [Internet]. Elsevier; 2018 [cited 2019 Dec 9]. pp. 314\u201340. Available from: http:\/\/www.sciencedirect.com\/science\/article\/pii\/B9780323265683000154","DOI":"10.1016\/B978-0-323-26568-3.00015-4"},{"issue":"30","key":"1750_CR33","doi-asserted-by":"publisher","first-page":"10275","DOI":"10.1073\/pnas.0805459105","volume":"105","author":"GJ Freeman","year":"2008","unstructured":"Freeman GJ. Structures of PD-1 with its ligands: sideways and dancing cheek to cheek. Proc Natl Acad Sci U S A. 2008;105(30):10275\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1750_CR34","doi-asserted-by":"crossref","unstructured":"Pardoll D. 52 - Cancer Immunotherapy with Vaccines and Checkpoint Blockade. In: Mendelsohn J, Gray JW, Howley PM, Israel MA, Thompson CB, editors. The Molecular Basis of Cancer (Fourth Edition) [Internet]. Philadelphia: Content Repository Only! 2015 [cited 2019 Dec 9]. pp. 709\u2013738.e8. Available from: http:\/\/www.sciencedirect.com\/science\/article\/pii\/B9781455740666000524","DOI":"10.1016\/B978-1-4557-4066-6.00052-4"},{"issue":"4","key":"1750_CR35","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nri3405","volume":"13","author":"L Chen","year":"2013","unstructured":"Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013;13(4):227\u201342.","journal-title":"Nat Rev Immunol"},{"key":"1750_CR36","doi-asserted-by":"crossref","unstructured":"Callahan MK, Postow MA, Wolchok JD. Chapter 19 - Antibodies to Stimulate Host Immunity: Lessons from Ipilimumab. In: Prendergast GC, Jaffee EM, editors. Cancer Immunotherapy (Second Edition) [Internet]. San Diego: Academic Press; 2013 [cited 2019 Dec 9]. pp. 287\u2013307. Available from: http:\/\/www.sciencedirect.com\/science\/article\/pii\/B9780123942968000191","DOI":"10.1016\/B978-0-12-394296-8.00019-1"},{"key":"1750_CR37","doi-asserted-by":"crossref","unstructured":"Ikemizu S, Davis SJ. Chapter 2 - Principles of Protein Recognition by Small T-Cell Adhesion Proteins and Costimulatory Receptors. In: Putterman C, Cowburn D, Almo S, editors. Structural Biology in Immunology [Internet]. Academic Press; 2018 [cited 2019 Dec 9]. pp. 39\u201380. Available from: http:\/\/www.sciencedirect.com\/science\/article\/pii\/B9780128033692000024","DOI":"10.1016\/B978-0-12-803369-2.00002-4"},{"key":"1750_CR38","doi-asserted-by":"crossref","unstructured":"Sekhon N, Kumbla RA, Mita M. Chapter 1 - Current Trends in Cancer Therapy. In: Gottlieb RA, Mehta PK, editors. Cardio-Oncology [Internet]. Boston: Academic Press; 2017 [cited 2019 Dec 9]. pp. 1\u201324. Available from: http:\/\/www.sciencedirect.com\/science\/article\/pii\/B978012803547400001X","DOI":"10.1016\/B978-0-12-803547-4.00001-X"},{"key":"1750_CR39","doi-asserted-by":"crossref","unstructured":"Mir MA. Chapter 5 - Costimulation in Lymphomas and Cancers. In: Mir MA, editor. Developing Costimulatory Molecules for Immunotherapy of Diseases [Internet]. Academic Press; 2015 [cited 2019 Dec 9]. pp. 185\u2013254. Available from: http:\/\/www.sciencedirect.com\/science\/article\/pii\/B9780128025857000054","DOI":"10.1016\/B978-0-12-802585-7.00005-4"},{"key":"1750_CR40","doi-asserted-by":"crossref","unstructured":"Joshi H, Press MF. 22 - Molecular Oncology of Breast Cancer. In: Bland KI, Copeland EM, Klimberg VS, Gradishar WJ, editors. The Breast (Fifth Edition) [Internet]. Elsevier; 2018 [cited 2019 Dec 9]. pp. 282\u2013307.e5. Available from: http:\/\/www.sciencedirect.com\/science\/article\/pii\/B9780323359559000222","DOI":"10.1016\/B978-0-323-35955-9.00022-2"},{"issue":"1","key":"1750_CR41","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/COC.0000000000000239","volume":"39","author":"EI Buchbinder","year":"2016","unstructured":"Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways. Am J Clin Oncol. 2016;39(1):98\u2013106.","journal-title":"Am J Clin Oncol"},{"key":"1750_CR42","doi-asserted-by":"crossref","unstructured":"Khalil DN, Budhu S, Gasmi B, Zappasodi R, Hirschhorn-Cymerman D, Plitt T et al. Chapter One - The New Era of Cancer Immunotherapy: Manipulating T-Cell Activity to Overcome Malignancy. In: Wang XY, Fisher PB, editors. Advances in Cancer Research [Internet]. Academic Press; 2015 [cited 2019 Dec 9]. pp. 1\u201368. (Immunotherapy of Cancer; vol. 128). Available from: http:\/\/www.sciencedirect.com\/science\/article\/pii\/S0065230X1500038X","DOI":"10.1016\/bs.acr.2015.04.010"},{"issue":"5","key":"1750_CR43","doi-asserted-by":"publisher","first-page":"eaay4458","DOI":"10.1126\/sciadv.aay4458","volume":"6","author":"M Marasco","year":"2020","unstructured":"Marasco M, Berteotti A, Weyershaeuser J, Thorausch N, Sikorska J, Krausze J, et al. Molecular mechanism of SHP2 activation by PD-1 stimulation. Sci Adv. 2020;6(5):eaay4458.","journal-title":"Sci Adv"},{"issue":"10","key":"1750_CR44","doi-asserted-by":"publisher","first-page":"5282","DOI":"10.3390\/ijms22105282","volume":"22","author":"L Chocarro","year":"2021","unstructured":"Chocarro L, Blanco E, Zuazo M, Arasanz H, Bocanegra A, Fern\u00e1ndez-Rubio L, et al. Understanding LAG-3 signaling. Int J Mol Sci. 2021;22(10):5282.","journal-title":"Int J Mol Sci"},{"issue":"23","key":"1750_CR45","doi-asserted-by":"publisher","first-page":"5030","DOI":"10.1158\/1078-0432.CCR-21-2390","volume":"28","author":"LP Andrews","year":"2022","unstructured":"Andrews LP, Cillo AR, Karapetyan L, Kirkwood JM, Workman CJ, Vignali DAA. Molecular pathways and mechanisms of LAG3 in cancer therapy. Clin Cancer Res Off J Am Assoc Cancer Res. 2022;28(23):5030\u20139.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"1","key":"1750_CR46","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3390\/v15010147","volume":"15","author":"L Rodr\u00edguez-Guilarte","year":"2023","unstructured":"Rodr\u00edguez-Guilarte L, Ram\u00edrez MA, Andrade CA, Kalergis AM. LAG-3 contribution to T cell downmodulation during acute respiratory viral infections. Viruses. 2023;15(1):147.","journal-title":"Viruses"},{"issue":"2","key":"1750_CR47","first-page":"135","volume":"14","author":"N Zila","year":"2021","unstructured":"Zila N, Hoeller C, Paulitschke V. Novel immune checkpoints beyond PD-1 in advanced melanoma. Memo - Mag Eur Med Oncol. 2021;14(2):135\u201342.","journal-title":"Memo - Mag Eur Med Oncol"},{"key":"1750_CR48","doi-asserted-by":"publisher","first-page":"S185","DOI":"10.1016\/j.semcancer.2015.03.004","volume":"35","author":"DS Vinay","year":"2015","unstructured":"Vinay DS, Ryan EP, Pawelec G, Talib WH, Stagg J, Elkord E, et al. Immune evasion in cancer: mechanistic basis and therapeutic strategies. Semin Cancer Biol. 2015;35:S185\u201398.","journal-title":"Semin Cancer Biol"},{"issue":"5","key":"1750_CR49","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646\u201374.","journal-title":"Cell"},{"issue":"1","key":"1750_CR50","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s12935-023-03157-5","volume":"23","author":"R Li","year":"2023","unstructured":"Li R, Qiu J, Zhang Z, Qu C, Tang Z, Yu W, et al. Prognostic significance of Lymphocyte-activation gene 3 (LAG3) in patients with solid tumors: a systematic review, meta-analysis and pan-cancer analysis. Cancer Cell Int. 2023;23(1):306.","journal-title":"Cancer Cell Int"},{"key":"1750_CR51","doi-asserted-by":"crossref","unstructured":"Hadash-Bengad R, Hajaj E, Klein S, Merims S, Frank S, Eisenberg G et al. Immunotherapy Potentiates the Effect of Chemotherapy in Metastatic Melanoma\u2014A Retrospective Study. Front Oncol [Internet]. 2020 Feb 14 [cited 2021 Mar 9];10. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7033746\/","DOI":"10.3389\/fonc.2020.00070"},{"key":"1750_CR52","unstructured":"Nivolumab\u2013relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over (2024) NICE technology appraisal 950."},{"issue":"3","key":"1750_CR53","doi-asserted-by":"publisher","first-page":"738","DOI":"10.3390\/cancers12030738","volume":"12","author":"RK Vaddepally","year":"2020","unstructured":"Vaddepally RK, Kharel P, Pandey R, Garje R, Chandra AB. Review of indications of FDA-Approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. Cancers. 2020;12(3):738.","journal-title":"Cancers"},{"issue":"2","key":"1750_CR54","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3892\/mi.2024.137","volume":"4","author":"V Shah","year":"2024","unstructured":"Shah V, Panchal V, Shah A, Vyas B, Agrawal S, Bharadwaj S. Immune checkpoint inhibitors in metastatic melanoma therapy (Review). Med Int. 2024;4(2):13.","journal-title":"Med Int"},{"issue":"17","key":"1750_CR55","doi-asserted-by":"publisher","first-page":"5191","DOI":"10.1158\/1078-0432.CCR-18-1550","volume":"25","author":"SA Weiss","year":"2019","unstructured":"Weiss SA, Wolchok JD, Sznol M. Immunotherapy of melanoma: facts and hopes. Clin Cancer Res. 2019;25(17):5191\u2013201.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"1750_CR56","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/s41590-022-01141-1","volume":"23","author":"AC Huang","year":"2022","unstructured":"Huang AC, Zappasodi R. A decade of checkpoint Blockade immunotherapy in melanoma: Understanding the molecular basis for immune sensitivity and resistance. Nat Immunol. 2022;23(5):660\u201370.","journal-title":"Nat Immunol"},{"issue":"Suppl 1","key":"1750_CR57","first-page":"S11","volume":"6","author":"MB Atkins","year":"2000","unstructured":"Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose Recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am. 2000;6(Suppl 1):S11\u201314.","journal-title":"Cancer J Sci Am"},{"issue":"10","key":"1750_CR58","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.1093\/annonc\/mdt291","volume":"24","author":"D McDermott","year":"2013","unstructured":"McDermott D, Haanen J, Chen TT, Lorigan P, O\u2019Day S. Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20). Ann Oncol. 2013;24(10):2694\u20138.","journal-title":"Ann Oncol"},{"issue":"19","key":"1750_CR59","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","volume":"375","author":"AMM Eggermont","year":"2016","unstructured":"Eggermont AMM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med. 2016;375(19):1845\u201355.","journal-title":"N Engl J Med"},{"key":"1750_CR60","unstructured":"National Library of Medicine. Study of pembrolizumab (MK-3475) versus ipilimumab in participants with advanced melanoma (MK-3475-006\/KEYNOTE-006) [Internet]. ClinicalTrials.gov; [cited 2025 Feb 6]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT01295827"},{"issue":"4","key":"1750_CR61","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1093\/annonc\/mdz011","volume":"01","author":"O Hamid","year":"2019","unstructured":"Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol Off J Eur Soc Med Oncol. 2019;01(4):582\u20138.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"1750_CR62","doi-asserted-by":"publisher","unstructured":"Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L et al. https:\/\/doi.org\/10.1056\/NEJMoa1503093. 2015 [cited 2019 Dec 9]. Pembrolizumab versus Ipilimumab in Advanced Melanoma. Available from: https:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa1503093","DOI":"10.1056\/NEJMoa1503093"},{"issue":"19","key":"1750_CR63","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","volume":"378","author":"AMM Eggermont","year":"2018","unstructured":"Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378(19):1789\u2013801.","journal-title":"N Engl J Med"},{"issue":"4","key":"1750_CR64","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s00428-019-02538-4","volume":"474","author":"M Ottaviano","year":"2019","unstructured":"Ottaviano M, De Placido S, Ascierto PA. Recent success and limitations of immune checkpoint inhibitors for cancer: a lesson from melanoma. Virchows Arch. 2019;474(4):421\u201332.","journal-title":"Virchows Arch"},{"issue":"4","key":"1750_CR65","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","volume":"16","author":"JS Weber","year":"2015","unstructured":"Weber JS, D\u2019Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16(4):375\u201384.","journal-title":"Lancet Oncol"},{"issue":"8","key":"1750_CR66","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711\u201323.","journal-title":"N Engl J Med"},{"issue":"4","key":"1750_CR67","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1200\/JCO.2017.72.2850","volume":"36","author":"MK Callahan","year":"2017","unstructured":"Callahan MK, Kluger H, Postow MA, Segal NH, Lesokhin A, Atkins MB, et al. Nivolumab plus ipilimumab in patients with advanced melanoma: updated Survival, Response, and safety data in a phase I Dose-Escalation study. J Clin Oncol. 2017;36(4):391\u20138.","journal-title":"J Clin Oncol"},{"issue":"11","key":"1750_CR68","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1016\/S1470-2045(16)30366-7","volume":"17","author":"FS Hodi","year":"2016","unstructured":"Hodi FS, Chesney J, Pavlick AC, Robert C, Grossmann KF, McDermott DF, et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. 2016;17(11):1558\u201368.","journal-title":"Lancet Oncol"},{"issue":"14","key":"1750_CR69","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377(14):1345\u201356.","journal-title":"N Engl J Med"},{"issue":"6","key":"1750_CR70","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s11912-023-01406-4","volume":"25","author":"LJ Albrecht","year":"2023","unstructured":"Albrecht LJ, Livingstone E, Zimmer L, Schadendorf D. The latest option: nivolumab and relatlimab in advanced melanoma. Curr Oncol Rep. 2023;25(6):647\u201357.","journal-title":"Curr Oncol Rep"},{"issue":"10","key":"1750_CR71","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.7150\/jca.72210","volume":"13","author":"J Pradeep","year":"2022","unstructured":"Pradeep J, Win TT, Aye SN, Sreeramareddy CT. Efficacy and safety of immune checkpoint inhibitors for advanced malignant melanoma: A Meta-Analysis on monotherapy vs combination therapy. J Cancer. 2022;13(10):3091\u2013102.","journal-title":"J Cancer"},{"key":"1750_CR72","unstructured":"Responses to Pembrolizumab and Ipilimumab After Anti\u2013PD-1\/L1 Failure in Advanced Melanoma. - The ASCO Post [Internet]. [cited 2021 Jul 9]. Available from: https:\/\/ascopost.com\/news\/july-2021\/responses-to-pembrolizumab-and-ipilimumab-after-anti-pd-1l1-failure-in-advanced-melanoma\/?utm_source=TAP%2DEN%2D070221%2DINTL&utm_medium=email&utm_term=a418f600fc692d3db14763f364e82bbc?bc_md5=a418f600fc692d3db14763f364e82bbc"},{"key":"1750_CR73","doi-asserted-by":"crossref","unstructured":"Olson DJ, Eroglu Z, Brockstein B, Poklepovic AS, Bajaj M, Babu S et al. Pembrolizumab plus ipilimumab following Anti-PD-1\/L1 failure in melanoma. J Clin Oncol Off J Am Soc Clin Oncol. 2021;JCO2100079.","DOI":"10.1200\/JCO.21.00079"},{"issue":"6","key":"1750_CR74","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/S1470-2045(21)00097-8","volume":"22","author":"I Pires da Silva","year":"2021","unstructured":"Pires da Silva I, Ahmed T, Reijers ILM, Weppler AM, Betof Warner A, Patrinely JR, et al. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. Lancet Oncol. 2021;22(6):836\u201347.","journal-title":"Lancet Oncol"},{"issue":"9","key":"1750_CR75","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1038\/s41591-023-02498-y","volume":"29","author":"A VanderWalde","year":"2023","unstructured":"VanderWalde A, Bellasea SL, Kendra KL, Khushalani NI, Campbell KM, Scumpia PO, et al. Ipilimumab with or without nivolumab in PD1\/PDL1 Blockade refractory metastatic melanoma: a randomized phase 2 trial. Nat Med. 2023;29(9):2278\u201385.","journal-title":"Nat Med"},{"issue":"15suppl","key":"1750_CR76","doi-asserted-by":"publisher","first-page":"9520","DOI":"10.1200\/JCO.2017.35.15_suppl.9520","volume":"35","author":"PA Ascierto","year":"2017","unstructured":"Ascierto PA, Melero I, Bhatia S, Bono P, Sanborn RE, Lipson EJ, et al. Initial efficacy of anti-lymphocyte activation gene-3 (anti\u2013LAG-3; BMS-986016) in combination with nivolumab (nivo) in Pts with melanoma (MEL) previously treated with anti\u2013PD-1\/PD-L1 therapy. J Clin Oncol. 2017;35(15suppl):9520\u20139520.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1750_CR77","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1056\/NEJMe2116892","volume":"386","author":"AE Frampton","year":"2022","unstructured":"Frampton AE, Sivakumar S. A new combination immunotherapy in advanced melanoma. N Engl J Med. 2022;386(1):91\u20132.","journal-title":"N Engl J Med"},{"key":"1750_CR78","doi-asserted-by":"crossref","unstructured":"Chavanton A, Mialhe F, Abrey J, Baeza Garcia A, Garrido C. LAG-3 : recent developments in combinational therapies in cancer. Cancer Sci. 2024 Aug;115(8):2494-2505.","DOI":"10.1111\/cas.16205"},{"key":"1750_CR79","doi-asserted-by":"crossref","unstructured":"Hieken TJ, Kreidieh F, Aedo-Lopez V, Block MS, McArthur GA, Amaria RN. Neoadjuvant immunotherapy in melanoma: the paradigm shift. Am Soc Clin Oncol Educ Book. 2023; 43:e390614.","DOI":"10.1200\/EDBK_390614"},{"issue":"9","key":"1750_CR80","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1056\/NEJMoa2211437","volume":"388","author":"SP Patel","year":"2023","unstructured":"Patel SP, Othus M, Chen Y, Wright GP, Yost KJ, Hyngstrom JR, et al. Neoadjuvant\u2013Adjuvant or Adjuvant-Only pembrolizumab in advanced melanoma. N Engl J Med. 2023;388(9):813\u201323.","journal-title":"N Engl J Med"},{"issue":"30","key":"1750_CR81","doi-asserted-by":"publisher","first-page":"4794","DOI":"10.1200\/JCO.23.01136","volume":"41","author":"R Seth","year":"2023","unstructured":"Seth R, Agarwala SS, Messersmith H, Alluri KC, Ascierto PA, Atkins MB, et al. Systemic therapy for melanoma: ASCO guideline update. J Clin Oncol. 2023;41(30):4794\u2013820.","journal-title":"J Clin Oncol"},{"issue":"11","key":"1750_CR82","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1038\/s41591-018-0198-0","volume":"24","author":"CU Blank","year":"2018","unstructured":"Blank CU, Rozeman EA, Fanchi LF, Sikorska K, van de Wiel B, Kvistborg P, et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat Med. 2018;24(11):1655\u201361.","journal-title":"Nat Med"},{"issue":"18","key":"1750_CR83","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1056\/NEJMoa2402604","volume":"391","author":"CU Blank","year":"2024","unstructured":"Blank CU, Lucas MW, Scolyer RA, van de Wiel BA, Menzies AM, Lopez-Yurda M, et al. Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma. N Engl J Med. 2024;391(18):1696\u2013708.","journal-title":"N Engl J Med"},{"issue":"21","key":"1750_CR84","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","volume":"386","author":"PM Forde","year":"2022","unstructured":"Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386(21):1973\u201385.","journal-title":"N Engl J Med"},{"issue":"1","key":"1750_CR85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21873\/anticanres.14746","volume":"41","author":"KS Rallis","year":"2021","unstructured":"Rallis KS, Yau THL, Sideris M. Chemoradiotherapy in cancer treatment: rationale and clinical applications. Anticancer Res. 2021;41(1):1\u20137.","journal-title":"Anticancer Res"},{"issue":"5","key":"1750_CR86","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1084\/jem.20052494","volume":"203","author":"EA Reits","year":"2006","unstructured":"Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, Wansley EK, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med. 2006;203(5):1259\u201371.","journal-title":"J Exp Med"},{"key":"1750_CR87","doi-asserted-by":"publisher","first-page":"e28518","DOI":"10.4161\/onci.28518","volume":"3","author":"EB Golden","year":"2014","unstructured":"Golden EB, Frances D, Pellicciotta I, Demaria S, Helen Barcellos-Hoff M, Formenti SC. Radiation fosters dose-dependent and chemotherapy-induced Immunogenic cell death. Oncoimmunology. 2014;3:e28518.","journal-title":"Oncoimmunology"},{"issue":"10","key":"1750_CR88","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1056\/NEJMoa1112824","volume":"366","author":"MA Postow","year":"2012","unstructured":"Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366(10):925\u201331.","journal-title":"N Engl J Med"},{"issue":"3","key":"1750_CR89","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.21873\/anticanres.14871","volume":"41","author":"KS Rallis","year":"2021","unstructured":"Rallis KS, Hillyar CRT, Sideris M, Davies JK. T-cell-based immunotherapies for haematological Cancers, part B: A SWOT analysis of adoptive cell therapies. Anticancer Res. 2021;41(3):1143\u201356.","journal-title":"Anticancer Res"},{"issue":"26","key":"1750_CR90","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","volume":"364","author":"C Robert","year":"2011","unstructured":"Robert C, Thomas L, Bondarenko I, O\u2019Day S, Weber J, Garbe C, et al. Ipilimumab plus Dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517\u201326.","journal-title":"N Engl J Med"},{"issue":"9","key":"1750_CR91","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1158\/2326-6066.CIR-14-0069","volume":"2","author":"C Tang","year":"2014","unstructured":"Tang C, Wang X, Soh H, Seyedin S, Cortez MA, Krishnan S, et al. Combining radiation and immunotherapy: a new systemic therapy for solid tumors? Cancer Immunol Res. 2014;2(9):831\u20138.","journal-title":"Cancer Immunol Res"},{"key":"1750_CR92","first-page":"7","volume":"13","author":"J Weber","year":"2013","unstructured":"Weber J, Hamid O, Amin A, O\u2019Day S, Masson E, Goldberg SM, et al. Randomized phase I Pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma. Cancer Immun. 2013;13:7.","journal-title":"Cancer Immun"},{"issue":"4","key":"1750_CR93","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1097\/CMR.0000000000000669","volume":"30","author":"J Vera Aguilera","year":"2020","unstructured":"Vera Aguilera J, Paludo J, McWilliams RR, Zhang H, Li Y, Kumar AB, et al. Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients. Melanoma Res. 2020;30(4):364\u201375.","journal-title":"Melanoma Res"},{"issue":"9","key":"1750_CR94","doi-asserted-by":"publisher","first-page":"e839","DOI":"10.1093\/oncolo\/oyad184","volume":"28","author":"RS Goodman","year":"2023","unstructured":"Goodman RS, Jung S, Quintos J, Johnson DB. Therapeutic responses to combination nivolumab and Temozolomide as salvage therapy for metastatic melanoma: A case series. Oncologist. 2023;28(9):e839\u201342.","journal-title":"Oncologist"},{"issue":"1","key":"1750_CR95","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1080\/15384047.2016.1264543","volume":"18","author":"KM Koller","year":"2017","unstructured":"Koller KM, Mackley HB, Liu J, Wagner H, Talamo G, Schell TD, et al. Improved survival and complete response rates in patients with advanced melanoma treated with concurrent ipilimumab and radiotherapy versus ipilimumab alone. Cancer Biol Ther. 2017;18(1):36\u201342.","journal-title":"Cancer Biol Ther"},{"issue":"1","key":"1750_CR96","doi-asserted-by":"publisher","first-page":"e000395","DOI":"10.1136\/jitc-2019-000395","volume":"8","author":"S Knispel","year":"2020","unstructured":"Knispel S, Stang A, Zimmer L, Lax H, Gutzmer R, Heinzerling L, et al. Impact of a preceding radiotherapy on the outcome of immune checkpoint Inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOG. J Immunother Cancer. 2020;8(1):e000395.","journal-title":"J Immunother Cancer"},{"key":"1750_CR97","doi-asserted-by":"publisher","first-page":"102499","DOI":"10.1016\/j.ctrv.2022.102499","volume":"113","author":"DC Ziogas","year":"2023","unstructured":"Ziogas DC, Theocharopoulos C, Koutouratsas T, Haanen J, Gogas H. Mechanisms of resistance to immune checkpoint inhibitors in melanoma: what we have to overcome? Cancer Treat Rev. 2023;113:102499.","journal-title":"Cancer Treat Rev"},{"issue":"7","key":"1750_CR98","doi-asserted-by":"publisher","first-page":"835","DOI":"10.3390\/biomedicines9070835","volume":"9","author":"S Vukadin","year":"2021","unstructured":"Vukadin S, Khaznadar F, Kizivat T, Vcev A, Smolic M. Molecular mechanisms of resistance to immune checkpoint inhibitors in melanoma treatment: an update. Biomedicines. 2021;9(7):835.","journal-title":"Biomedicines"},{"issue":"4","key":"1750_CR99","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.3390\/cancers15041106","volume":"15","author":"A Knight","year":"2023","unstructured":"Knight A, Karapetyan L, Kirkwood JM. Immunotherapy in melanoma: recent advances and future directions. Cancers. 2023;15(4):1106.","journal-title":"Cancers"},{"issue":"10304","key":"1750_CR100","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","volume":"398","author":"MS Carlino","year":"2021","unstructured":"Carlino MS, Larkin J, Long GV. Immune checkpoint inhibitors in melanoma. Lancet. 2021;398(10304):1002\u201314.","journal-title":"Lancet"},{"key":"1750_CR101","doi-asserted-by":"publisher","first-page":"779691","DOI":"10.3389\/fimmu.2022.779691","volume":"13","author":"A Chennamadhavuni","year":"2022","unstructured":"Chennamadhavuni A, Abushahin L, Jin N, Presley CJ, Manne A. Risk factors and biomarkers for immune-Related adverse events: A practical guide to identifying High-Risk patients and rechallenging immune checkpoint inhibitors. Front Immunol. 2022;13:779691.","journal-title":"Front Immunol"},{"issue":"7","key":"1750_CR102","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.trecan.2023.04.002","volume":"9","author":"SJ Wang","year":"2023","unstructured":"Wang SJ, Dougan SK, Dougan M. Immune mechanisms of toxicity from checkpoint inhibitors. Trends Cancer. 2023;9(7):543\u201353.","journal-title":"Trends Cancer"},{"issue":"4","key":"1750_CR103","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","volume":"19","author":"DB Johnson","year":"2022","unstructured":"Johnson DB, Nebhan CA, Moslehi JJ, Balko JM. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol. 2022;19(4):254\u201367.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"1750_CR104","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/imr.13249","volume":"318","author":"RS Goodman","year":"2023","unstructured":"Goodman RS, Jung S, Balko JM, Johnson DB. Biomarkers of immune checkpoint inhibitor response and toxicity: challenges and opportunities. Immunol Rev. 2023;318(1):157\u201366.","journal-title":"Immunol Rev"},{"issue":"5","key":"1750_CR105","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1053\/sonc.2002.35238","volume":"29","author":"E Bajetta","year":"2002","unstructured":"Bajetta E, Del Vecchio M, Bernard-Marty C, Vitali M, Buzzoni R, Rixe O, et al. Metastatic melanoma: chemotherapy. Semin Oncol. 2002;29(5):427\u201345.","journal-title":"Semin Oncol"},{"issue":"4","key":"1750_CR106","first-page":"287","volume":"24","author":"DJ Schwartzentruber","year":"2001","unstructured":"Schwartzentruber DJ. Guidelines for the safe administration of high-dose interleukin-2. J Immunother Hagerstown Md 1997. 2001;24(4):287\u201393.","journal-title":"J Immunother Hagerstown Md 1997"},{"key":"1750_CR107","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.ejca.2022.12.013","volume":"181","author":"SK Wong","year":"2023","unstructured":"Wong SK, Blum SM, Sun X, Da Silva IP, Zubiri L, Ye F, et al. Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanoma. Eur J Cancer. 2023;181:188\u201397.","journal-title":"Eur J Cancer"},{"issue":"3","key":"1750_CR108","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s40257-022-00681-4","volume":"23","author":"F Aroldi","year":"2022","unstructured":"Aroldi F, Middleton MR. Long-Term outcomes of immune checkpoint Inhibition in metastatic melanoma. Am J Clin Dermatol. 2022;23(3):331\u20138.","journal-title":"Am J Clin Dermatol"},{"issue":"12","key":"1750_CR109","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, et al. Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and Meta-analysis. JAMA Oncol. 2018;4(12):1721\u20138.","journal-title":"JAMA Oncol"},{"issue":"1","key":"1750_CR110","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","volume":"386","author":"HA Tawbi","year":"2022","unstructured":"Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Guti\u00e9rrez E, et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med. 2022;386(1):24\u201334.","journal-title":"N Engl J Med"},{"issue":"11","key":"1750_CR111","doi-asserted-by":"publisher","first-page":"e23236","DOI":"10.1096\/fj.202301018R","volume":"37","author":"Y Li","year":"2023","unstructured":"Li Y, Ju M, Miao Y, Zhao L, Xing L, Wei M. Advancement of anti-LAG \u20103 in cancer therapy. FASEB J. 2023;37(11):e23236.","journal-title":"FASEB J"},{"issue":"1","key":"1750_CR112","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12943-019-1091-2","volume":"18","author":"S Qin","year":"2019","unstructured":"Qin S, Xu L, Yi M, Yu S, Wu K, Luo S. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer. 2019;18(1):155.","journal-title":"Mol Cancer"},{"issue":"3","key":"1750_CR113","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41577-019-0224-6","volume":"20","author":"Y Wolf","year":"2020","unstructured":"Wolf Y, Anderson AC, Kuchroo VK. TIM3 comes of age as an inhibitory receptor. Nat Rev Immunol. 2020;20(3):173\u201385.","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"1750_CR114","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1084\/jem.20100643","volume":"207","author":"K Sakuishi","year":"2010","unstructured":"Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med. 2010;207(10):2187\u201394.","journal-title":"J Exp Med"},{"key":"1750_CR115","doi-asserted-by":"publisher","first-page":"10501","DOI":"10.1038\/ncomms10501","volume":"7","author":"S Koyama","year":"2016","unstructured":"Koyama S, Akbay EA, Li YY, Herter-Sprie GS, Buczkowski KA, Richards WG, et al. Adaptive resistance to therapeutic PD-1 Blockade is associated with upregulation of alternative immune checkpoints. Nat Commun. 2016;7:10501.","journal-title":"Nat Commun"},{"issue":"10","key":"1750_CR116","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.1158\/0008-5472.CAN-11-0096","volume":"71","author":"SF Ngiow","year":"2011","unstructured":"Ngiow SF, von Scheidt B, Akiba H, Yagita H, Teng MWL, Smyth MJ. Anti-TIM3 antibody promotes T cell IFN-\u03b3\u2013Mediated antitumor immunity and suppresses established tumors. Cancer Res. 2011;71(10):3540\u201351.","journal-title":"Cancer Res"},{"issue":"4","key":"1750_CR117","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1158\/0008-5472.CAN-11-2637","volume":"72","author":"J Fourcade","year":"2012","unstructured":"Fourcade J, Sun Z, Pagliano O, Guillaume P, Luescher IF, Sander C, et al. CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res. 2012;72(4):887\u201396.","journal-title":"Cancer Res"},{"issue":"10","key":"1750_CR118","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.3390\/cancers15102718","volume":"15","author":"DC Ziogas","year":"2023","unstructured":"Ziogas DC, Theocharopoulos C, Lialios PP, Foteinou D, Koumprentziotis IA, Xynos G, et al. Beyond CTLA-4 and PD-1 inhibition: novel immune checkpoint molecules for melanoma treatment. Cancers. 2023;15(10):2718.","journal-title":"Cancers"},{"issue":"7","key":"1750_CR119","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s00262-018-2169-1","volume":"67","author":"LF Kuklinski","year":"2018","unstructured":"Kuklinski LF, Yan S, Li Z, Fisher JL, Cheng C, Noelle RJ, et al. VISTA expression on tumor-infiltrating inflammatory cells in primary cutaneous melanoma correlates with poor disease-specific survival. Cancer Immunol Immunother. 2018;67(7):1113\u201321.","journal-title":"Cancer Immunol Immunother"},{"key":"1750_CR120","doi-asserted-by":"publisher","first-page":"v405","DOI":"10.1093\/annonc\/mdx376.007","volume":"28","author":"J Powderly","year":"2017","unstructured":"Powderly J, Patel MR, Lee JJ, Brody J, Meric-Bernstam F, Hamilton E, et al. CA-170, a first in class oral small molecule dual inhibitor of immune checkpoints PD-L1 and VISTA, demonstrates tumor growth Inhibition in pre-clinical models and promotes T cell activation in phase 1 study. Ann Oncol. 2017;28:v405\u20136.","journal-title":"Ann Oncol"},{"issue":"6382","key":"1750_CR121","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June CH, O\u2019Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359(6382):1361\u20135.","journal-title":"Science"},{"key":"1750_CR122","unstructured":"Adoptive cell transfer therapy [Internet]. Melanoma Research Alliance. [cited 2024 May 10]. Available from: https:\/\/www.curemelanoma.org\/patient-eng\/melanoma-treatment\/therapies-in-development\/adoptive-cell-transfer-therapy#panel-clinical-trial-locator"},{"issue":"4257","key":"1750_CR123","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1126\/science.181845","volume":"193","author":"DA Morgan","year":"1976","unstructured":"Morgan DA, Ruscetti FW, Gallo R. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science. 1976;193(4257):1007\u20138.","journal-title":"Science"},{"issue":"23","key":"1750_CR124","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1056\/NEJM198512053132327","volume":"313","author":"SA Rosenberg","year":"1985","unstructured":"Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and Recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985;313(23):1485\u201392.","journal-title":"N Engl J Med"},{"issue":"3","key":"1750_CR125","first-page":"989","volume":"138","author":"LM Muul","year":"1987","unstructured":"Muul LM, Spiess PJ, Director EP, Rosenberg SA. Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J Immunol Baltim Md 1950. 1987;138(3):989\u201395.","journal-title":"J Immunol Baltim Md 1950"},{"issue":"25","key":"1750_CR126","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1056\/NEJM198812223192527","volume":"319","author":"SA Rosenberg","year":"1988","unstructured":"Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988;319(25):1676\u201380.","journal-title":"N Engl J Med"},{"issue":"12","key":"1750_CR127","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1093\/annonc\/mdz398","volume":"30","author":"U Dafni","year":"2019","unstructured":"Dafni U, Michielin O, Lluesma SM, Tsourti Z, Polydoropoulou V, Karlis D, et al. Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and Recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis. Ann Oncol. 2019;30(12):1902\u201313.","journal-title":"Ann Oncol"},{"issue":"6704","key":"1750_CR128","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1126\/science.adp1130","volume":"385","author":"SA Rosenberg","year":"2024","unstructured":"Rosenberg SA. Lymphocytes as a living drug for cancer. Science. 2024;385(6704):25\u20136.","journal-title":"Science"},{"issue":"5594","key":"1750_CR129","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1126\/science.1076514","volume":"298","author":"ME Dudley","year":"2002","unstructured":"Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298(5594):850\u20134.","journal-title":"Science"},{"issue":"3","key":"1750_CR130","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s40291-024-00708-y","volume":"28","author":"SJ Keam","year":"2024","unstructured":"Keam SJ, Lifileucel. First approval. Mol Diagn Ther. 2024;28(3):339\u201344.","journal-title":"Mol Diagn Ther"},{"key":"1750_CR131","unstructured":"Klobuch S, Seijkens TTP, Schumacher TN, Haanen JBAG. Tumour-infiltrating lymphocyte therapy for patients with advanced-stage melanoma. Nat Rev Clin Oncol [Internet]. 2024;[cited 2024 Aug 6]; Available from: https:\/\/www.nature.com\/articles\/s41571-023-00848-w"},{"key":"1750_CR132","unstructured":"Center for Drug Evaluation and Research. FDA grants accelerated approval to lifileucel for unresectable or metastatic melanoma, U.S. Food and Drug Administration. Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-lifileucel-unresectable-or-metastatic-melanoma (Accessed: 06 August 2024)."},{"issue":"12","key":"1750_CR133","doi-asserted-by":"publisher","first-page":"e005755","DOI":"10.1136\/jitc-2022-005755","volume":"10","author":"J Chesney","year":"2022","unstructured":"Chesney J, Lewis KD, Kluger H, Hamid O, Whitman E, Thomas S, et al. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study. J Immunother Cancer. 2022;10(12):e005755.","journal-title":"J Immunother Cancer"},{"issue":"23","key":"1750_CR134","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa2210233","volume":"387","author":"MW Rohaan","year":"2022","unstructured":"Rohaan MW, Borch TH, Van Den Berg JH, Met \u00d6, Kessels R, Geukes Foppen MH, et al. Tumor-Infiltrating lymphocyte therapy or ipilimumab in advanced melanoma. N Engl J Med. 2022;387(23):2113\u201325.","journal-title":"N Engl J Med"},{"key":"1750_CR135","doi-asserted-by":"publisher","first-page":"44","DOI":"10.3389\/fonc.2018.00044","volume":"8","author":"JE Mullinax","year":"2018","unstructured":"Mullinax JE, Hall M, Prabhakaran S, Weber J, Khushalani N, Eroglu Z, et al. Combination of ipilimumab and adoptive cell therapy with Tumor-Infiltrating lymphocytes for patients with metastatic melanoma. Front Oncol. 2018;8:44.","journal-title":"Front Oncol"},{"issue":"24","key":"1750_CR136","doi-asserted-by":"publisher","first-page":"5317","DOI":"10.1158\/1078-0432.CCR-22-2103","volume":"28","author":"MS Hall","year":"2022","unstructured":"Hall MS, Mullinax JE, Cox CA, Hall AM, Beatty MS, Blauvelt J, et al. Combination Nivolumab, CD137 Agonism, and adoptive cell therapy with Tumor-Infiltrating lymphocytes for patients with metastatic melanoma. Clin Cancer Res. 2022;28(24):5317\u201329.","journal-title":"Clin Cancer Res"},{"issue":"19","key":"1750_CR137","doi-asserted-by":"publisher","first-page":"5289","DOI":"10.1158\/1078-0432.CCR-21-1171","volume":"27","author":"SJ Seitter","year":"2021","unstructured":"Seitter SJ, Sherry RM, Yang JC, Robbins PF, Shindorf ML, Copeland AR, et al. Impact of prior treatment on the efficacy of adoptive transfer of Tumor-Infiltrating lymphocytes in patients with metastatic melanoma. Clin Cancer Res Off J Am Assoc Cancer Res. 2021;27(19):5289\u201398.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"1","key":"1750_CR138","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1080\/17460441.2020.1811673","volume":"16","author":"MD Kerr","year":"2021","unstructured":"Kerr MD, McBride DA, Chumber AK, Shah NJ. Combining therapeutic vaccines with chemo- and immunotherapies in the treatment of cancer. Expert Opin Drug Discov. 2021;16(1):89\u201399.","journal-title":"Expert Opin Drug Discov"},{"issue":"10","key":"1750_CR139","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.3390\/vaccines9101060","volume":"9","author":"M Bidram","year":"2021","unstructured":"Bidram M, Zhao Y, Shebardina NG, Baldin AV, Bazhin AV, Ganjalikhany MR, et al. mRNA-Based cancer vaccines: A therapeutic strategy for the treatment of melanoma patients. Vaccines. 2021;9(10):1060.","journal-title":"Vaccines"},{"issue":"17","key":"1750_CR140","first-page":"2159","volume":"12","author":"M Kaczmarek","year":"2023","unstructured":"Kaczmarek M, Pozna\u0144ska J, Fechner F, Michalska N, Paszkowska S, Napiera\u0142a A, et al. Cancer Vaccine Therapeutics: Limitations Effectiveness\u2014A Literature Rev Cells. 2023;12(17):2159.","journal-title":"Cancer Vaccine Therapeutics: Limitations Effectiveness\u2014A Literature Rev Cells"},{"issue":"2","key":"1750_CR141","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/S1470-2045(23)00011-6","volume":"24","author":"U Samarasekera","year":"2023","unstructured":"Samarasekera U. New partnership to boost UK cancer vaccine research. Lancet Oncol. 2023;24(2):132.","journal-title":"Lancet Oncol"},{"issue":"17suppl","key":"1750_CR142","doi-asserted-by":"publisher","first-page":"LBA9503","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA9503","volume":"41","author":"A Khattak","year":"2023","unstructured":"Khattak A, Weber JS, Meniawy T, Taylor MH, Ansstas G, Kim KB, et al. Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201\/KEYNOTE-942 trial. J Clin Oncol. 2023;41(17suppl):LBA9503\u20139503.","journal-title":"J Clin Oncol"},{"issue":"10427","key":"1750_CR143","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","volume":"403","author":"JS Weber","year":"2024","unstructured":"Weber JS, Carlino MS, Khattak A, Meniawy T, Ansstas G, Taylor MH, et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet Lond Engl. 2024;403(10427):632\u201344.","journal-title":"Lancet Lond Engl"},{"key":"1750_CR144","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.semcancer.2022.12.003","volume":"88","author":"M Oladejo","year":"2023","unstructured":"Oladejo M, Paulishak W, Wood L. Synergistic potential of immune checkpoint inhibitors and therapeutic cancer vaccines. Semin Cancer Biol. 2023;88:81\u201395.","journal-title":"Semin Cancer Biol"},{"key":"1750_CR145","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3389\/fonc.2017.00202","volume":"7","author":"SR Jhawar","year":"2017","unstructured":"Jhawar SR, Thandoni A, Bommareddy PK, Hassan S, Kohlhapp FJ, Goyal S, et al. Oncolytic Viruses-Natural and genetically engineered cancer immunotherapies. Front Oncol. 2017;7:202.","journal-title":"Front Oncol"},{"issue":"6","key":"1750_CR146","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.3390\/cancers13061383","volume":"13","author":"PF Ferrucci","year":"2021","unstructured":"Ferrucci PF, Pala L, Conforti F, Cocorocchio E. Talimogene Laherparepvec (T-VEC): an intralesional cancer immunotherapy for advanced melanoma. Cancers. 2021;13(6):1383.","journal-title":"Cancers"},{"issue":"1","key":"1750_CR147","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s40425-019-0623-z","volume":"7","author":"RHI Andtbacka","year":"2019","unstructured":"Andtbacka RHI, Collichio F, Harrington KJ, Middleton MR, Downey G, \u04e6hrling K, et al. Final analyses of optim: a randomized phase III trial of talimogene Laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III\u2013IV melanoma. J Immunother Cancer. 2019;7(1):145.","journal-title":"J Immunother Cancer"},{"issue":"2","key":"1750_CR148","doi-asserted-by":"publisher","first-page":"63","DOI":"10.31083\/j.fbl2702063","volume":"27","author":"C Robinson","year":"2022","unstructured":"Robinson C, Xu MM, Nair SK, Beasley GM, Rhodin KE. Oncolytic viruses in melanoma. Front Biosci Landmark Ed. 2022;27(2):63.","journal-title":"Front Biosci Landmark Ed"},{"issue":"1","key":"1750_CR149","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/s40425-019-0682-1","volume":"7","author":"S Thomas","year":"2019","unstructured":"Thomas S, Kuncheria L, Roulstone V, Kyula JN, Mansfield D, Bommareddy PK, et al. Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1. J Immunother Cancer. 2019;7(1):214.","journal-title":"J Immunother Cancer"},{"issue":"0","key":"1750_CR150","first-page":"JCO","volume":"0","author":"MK Wong","year":"2025","unstructured":"Wong MK, Milhem MM, Sacco JJ, Michels J, In GK, Mu\u00f1oz Couselo E, et al. RP1 combined with nivolumab in advanced Anti\u2013PD-1\u2013Failed melanoma (IGNYTE). J Clin Oncol. 2025;0(0):JCO\u201325.","journal-title":"J Clin Oncol"},{"key":"1750_CR151","unstructured":"Anticancer immunotherapy by CTLA-. 4 blockade relies on the gut microbiota | Science [Internet]. [cited 2021 Apr 27]. Available from: https:\/\/science.sciencemag.org\/content\/350\/6264\/1079"},{"issue":"6371","key":"1750_CR152","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","volume":"359","author":"B Routy","year":"2018","unstructured":"Routy B, Chatelier EL, Derosa L, Duong CPM, Alou MT, Daill\u00e8re R, et al. Gut Microbiome influences efficacy of PD-1\u2013based immunotherapy against epithelial tumors. Science. 2018;359(6371):91\u20137.","journal-title":"Science"},{"key":"1750_CR153","doi-asserted-by":"publisher","first-page":"106876","DOI":"10.1016\/j.intimp.2020.106876","volume":"88","author":"M Yang","year":"2020","unstructured":"Yang M, Wang Y, Yuan M, Tao M, Kong C, Li H, et al. Antibiotic administration shortly before or after immunotherapy initiation is correlated with poor prognosis in solid cancer patients: an up-to-date systematic review and meta-analysis. Int Immunopharmacol. 2020;88:106876.","journal-title":"Int Immunopharmacol"},{"key":"1750_CR154","doi-asserted-by":"crossref","unstructured":"Huang XZ, Gao P, Song YX, Xu Y, Sun JX, Chen XW et al. Antibiotic use and the efficacy of immune checkpoint inhibitors in cancer patients: a pooled analysis of 2740 cancer patients. Oncoimmunology [Internet]. 2019;[cited 2020 Nov 29];8(12). Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6844307\/","DOI":"10.1080\/2162402X.2019.1665973"},{"key":"1750_CR155","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.3332\/ecancer.2020.1148","volume":"14","author":"S Morganti","year":"2020","unstructured":"Morganti S, Curigliano G. Combinations using checkpoint Blockade to overcome resistance. Ecancermedicalscience. 2020;14:1148.","journal-title":"Ecancermedicalscience"},{"key":"1750_CR156","doi-asserted-by":"crossref","unstructured":"Haibe Y, El Husseini Z, El Sayed R, Shamseddine A. Resisting Resistance to Immune Checkpoint Therapy: A Systematic Review. Int J Mol Sci [Internet]. 2020;[cited 2021 Apr 27];21(17). Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7504220\/","DOI":"10.3390\/ijms21176176"},{"key":"1750_CR157","doi-asserted-by":"crossref","unstructured":"Evans S, Martini D, Magod B, Olsen T, Brown J, Yantorni L et al. 255 Efficacy of sequential immune checkpoint inhibition (ICI) in patients with genitourinary malignancies. J Immunother Cancer [Internet]. 2020;[cited 2021 Apr 27];8(Suppl 3). Available from: https:\/\/jitc.bmj.com\/content\/8\/Suppl_3\/A154","DOI":"10.1136\/jitc-2020-SITC2020.0255"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01750-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-026-01750-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01750-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:28:29Z","timestamp":1781638109000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-026-01750-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,6]]},"references-count":157,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1750"],"URL":"https:\/\/doi.org\/10.1007\/s11912-026-01750-1","relation":{},"ISSN":["1534-6269"],"issn-type":[{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,6]]},"assertion":[{"value":"7 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23"}}